185 related articles for article (PubMed ID: 12355430)
1. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.
Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G
Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal modulation of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA.
Okamoto H; Asamitsu K; Nishimura H; Kamatani N; Okamoto T
Biochem Biophys Res Commun; 2000 Dec; 279(2):494-9. PubMed ID: 11118314
[TBL] [Abstract][Full Text] [Related]
3. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.
Forlani G; Turrini F; Ghezzi S; Tedeschi A; Poli G; Accolla RS; Tosi G
J Transl Med; 2016 Apr; 14():94. PubMed ID: 27089879
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines.
Tosi G; De Lerma Barbaro A; D'Agostino A; Valle MT; Megiovanni AM; Manca F; Caputo A; Barbanti-Brodano G; Accolla RS
Eur J Immunol; 2000 Jan; 30(1):19-28. PubMed ID: 10602023
[TBL] [Abstract][Full Text] [Related]
5. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b.
Wimmer J; Fujinaga K; Taube R; Cujec TP; Zhu Y; Peng J; Price DH; Peterlin BM
Virology; 1999 Mar; 255(1):182-9. PubMed ID: 10049833
[TBL] [Abstract][Full Text] [Related]
6. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation.
Okamoto H; Cujec TP; Peterlin BM; Okamoto T
Virology; 2000 May; 270(2):337-44. PubMed ID: 10792993
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of Tat-associated kinase-independent transcriptional elongation from the human immunodeficiency virus type-1 long terminal repeat by a cellular enhancer.
West MJ; Karn J
EMBO J; 1999 Mar; 18(5):1378-86. PubMed ID: 10064603
[TBL] [Abstract][Full Text] [Related]
9. H. saimiri tyrosine-kinase interacting protein inhibits Tat function: a prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells.
Raymond AD; Hasham M; Tsygankov AY; Henderson EE
Virology; 2006 Sep; 352(2):253-67. PubMed ID: 16780912
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
Jiang MC; Lin JK; Chen SS
Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
[TBL] [Abstract][Full Text] [Related]
11. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity.
Zauli G; La Placa M; Vignoli M; Re MC; Gibellini D; Furlini G; Milani D; Marchisio M; Mazzoni M; Capitani S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):306-16. PubMed ID: 7552492
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of class II trans-activator function by HIV-1 tat in mouse cells is independent of competition for binding to cyclin T1.
Mudhasani R; Fontes JD
Mol Immunol; 2002 Jan; 38(7):539-46. PubMed ID: 11750655
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
15. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
Desfosses Y; Solis M; Sun Q; Grandvaux N; Van Lint C; Burny A; Gatignol A; Wainberg MA; Lin R; Hiscott J
J Virol; 2005 Jul; 79(14):9180-91. PubMed ID: 15994812
[TBL] [Abstract][Full Text] [Related]
16. Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3.
Nevado J; Tenbaum SP; Castillo AI; Sánchez-Pacheco A; Aranda A
J Mol Endocrinol; 2007 Jun; 38(6):587-601. PubMed ID: 17556530
[TBL] [Abstract][Full Text] [Related]
17. A protein phosphatase from human T cells augments tat transactivation of the human immunodeficiency virus type 1 long-terminal repeat.
Bharucha DC; Zhou M; Nekhai S; Brady JN; Shukla RR; Kumar A
Virology; 2002 Apr; 296(1):6-16. PubMed ID: 12036313
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
[TBL] [Abstract][Full Text] [Related]
19. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication.
Verhoef K; Koper M; Berkhout B
Virology; 1997 Oct; 237(2):228-36. PubMed ID: 9356335
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells.
Sarol LC; Imai K; Asamitsu K; Tetsuka T; Barzaga NG; Okamoto T
Biochem Biophys Res Commun; 2002 Mar; 291(4):890-6. PubMed ID: 11866448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
